Search | Clinical Trials Finder

Conditions: Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions: Discontinuation and Reinitiation of Tirzepatide; Other
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sub-acute Back Pain
Interventions: Naproxen, Carbidopa/Levodopa, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Neoplasm, Cancer
Interventions: Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more

Conditions: Forehead Rhytides, Glabellar Rhytides
Interventions: OnabotulinumtoxinA, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • Glendale, Arizona • Santa Monica, California + 6 more

Conditions: Alzheimer's Disease
Interventions: Placebo, Bepranemab; Other · Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 40
States / cities: Fresno, California • Fullerton, California • Irvine, California + 34 more

Conditions: Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: MSB11022, Humira®; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more

Conditions: Psoriatic Arthritis
Interventions: Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 59
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Muscular Atrophy Type I
Interventions: sodium phenylbutyrate; Drug
Lead sponsor: Westat; Other
Eligibility: 2 Months to 48 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions: Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab; Radiation · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 101
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more

Conditions: Drug Use
Interventions: Usual Care, QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks), QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Long Beach, California • Los Angeles, California

Conditions: Myasthenic Syndromes, Congenital
Interventions: amifampridine phosphate, Placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Anxiety Disorder of Childhood
Interventions: Child Anxiety Learning Modules (CALM), Child Anxiety Learning Modules--Relaxation (CALM-R); Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 5 Years to 12 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: West Hartford, Connecticut • Columbia, Maryland

Conditions: Ulcerative Colitis
Interventions: Lutikizumab, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 48
States / cities: Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more

Conditions: Non-segmental Vitiligo
Interventions: VYN201 Gel, Vehicle Gel; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Deprescribing
Interventions: Anticipated long-term use of medication, Period re-evaluation of medication; Other
Lead sponsor: University of Michigan; Other
Eligibility: 65 Years and older
Enrollment: 2,420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Etanercept, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 19
States / cities: Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Data-Driven Clinical Recommendations, Coached Data-Driven Clinical Recommendations; Behavioral
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 50 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Chronic Pain
Interventions: Hydrocodone ER; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 54
States / cities: Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more

Conditions: Hypersensitivity
Interventions: Mometasone furoate drug formulation (MFF) 1, Mometasone furoate drug formulation (MFF) 2; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions: Guanfacine (GFC), Cromolyn Sodium, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

Effect of L-dopa In Subacute Back Pain Population

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

mHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Efficacy Trial of the CALM Intervention

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Leveraging Behavioral Science to Improve Medicine Optimization Conversations With Older Adults

Psilocybin for Major Depressive Disorder (MDD)

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial